GenScript Biotech Corporation, a Cayman Islands-incorporated company, announced the grant of Restricted Shares under its 2021 RSA Scheme. On June 11, 2025, the company awarded a total of 6,777,120 Restricted Shares. Among these, 6,707,292 shares were allocated to certain employees, while 69,828 shares were granted to two individual consultants engaged in technical research and strategic advisory services. This announcement highlights the company's ongoing efforts to reward and align key personnel with its growth objectives. The restricted shares were granted at no purchase price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.